| Treatment of childhood kaposiform hemangioendothelioma with sirolimus. | |
| | |
MedLine Citation:
|
PMID: 20730884 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1 mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions. |
| | |
Authors:
|
Julie Blatt; Joseph Stavas; Billie Moats-Staats; John Woosley; Dean S Morrell |
Related Documents
:
|
18822934 - Diffuse cavernous hemangioma of the spleen with kasabach-merritt syndrome misdiagnosed ... 19022024 - Hemangioma of the sternum. 11448074 - The role of tc-99m rbc scintigraphy in the differential diagnosis of orbital cavernous ... 7586854 - Congenital pelvic arteriovenous malformation: a rare cause of sciatica. 1416394 - Idiopathic pulmonary fibrosis. quantitative assessment of lung pathology. comparison of... 20495634 - Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancr... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Pediatric blood & cancer Volume: 55 ISSN: 1545-5017 ISO Abbreviation: Pediatr Blood Cancer Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-10-28 Completed Date: 2010-11-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101186624 Medline TA: Pediatr Blood Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 1396-8 Citation Subset: IM |
Affiliation:
|
Division of Pediatric Hematology Oncology, Vascular Lesions Clinic, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. jblat@med.unc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
therapeutic use* Antibiotics, Antineoplastic / therapeutic use* Female Hemangioendothelioma / blood, drug therapy*, pathology Humans Infant Platelet Count Sirolimus / therapeutic use* Skin Neoplasms / blood, drug therapy*, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibiotics, Antineoplastic; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sexual function in adolescent and young adult survivors of lower extremity bone tumors.
Next Document: Breast metastases in children and adolescents with rhabdomyosarcoma: Experience of the Italian Soft ...